news is leaked to shorts and MM, who are pumping so the short happens at much higher prices and they can cash 50% gains on short covering. The dilution prices is around 2.5-2.7 range
The pump is not due to Nuvax, since there is no new data. The abstral drugs sales team needs a ramp up with more hiring and marketing, hence the pump. Shorts and MM know it, you don't
Watch out for dilution soon, higher the price better it is for shorts to pocket fat gains. Interestingly these short hedge funds are planning to offer GALE money, that becomes a short covering and GALE gets money. Short pocket 40-50% through placement and ride it for free
Beware and think hard, don't just bash me. You will lose 40-50% from current levels in flash. GALE is known for all these for years
By the way, when a company lists a "dilution price" it's not listed as being "around" any price. It would have listed a specific price. Nice try. How much did you lose shorting this stock so far?
Sentiment: Strong Buy
Space aliens live amongst us and zombies will be running amok. John Kennedy was killed by the illuminati and an asteroid will hit earth in 15 days. Watch out for plagues and temperatures rising by 30 degrees in the next 30 days. Buy bottled water and canned goods--it's your only hope. All of these predictions come with as much proof as yours.
Don't be ridiculous! The Illuminati don't exist. Besides, everyone knows it was the Republicans that killed Kennedy, they are to blame for all that goes wrong in the world. Those dirty rotten Republicans....oh they make me so mad!
; ) Gobble Gobble you turkeys!
This post is comical. Here is a clip from today's SA article by Stock Whisperer:
Galena's coverage initiation by Oppenheimer is an additional treat for the already positive trend for the share prices and only supports the strong sentiment towards the company.
Financially, Galena is stable to sustain its current operations and there is no looming threat of another offering. The company has approximately $60 million in cash, which include the proceeds from the secondary offering in September. The sales of Abstral are expected to increase over the next quarters, and the U.S. market for fentanyl products in 2012 of $400 million, only supports the case. Hence, there is a high likelihood that the company will be able to sustain further studies on NeuVax using its own resources rather than raising more funding, thereby reducing the risk of dilution.
In my opinion Galena is a fair investment, with major long term potential. The current price is a profitable entry point for long term investors as the share prices are bound to take off and will bring in huge gains.